Reshma Kewalramani sold $20M of VRTX
CEO & President at VERTEX PHARMACEUTICALS INC / MA. 40,000 shares at an average of $493.47, traded Feb 27, 2026, filed Mar 3, 2026.
Score components
- +25RoleCEO
- +25Trade size$19.7M at market
- +10Share of holdings soldSold 29% of holdings
- +15Cluster11 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -7.5%, 3m -10.4%, 6m +15.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000875320-26-000129, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 27, 2026 | SOpen-market sale Common Stock10b5-1 | -400 | $479.75 | $192k | 137,878 | Mar 3, 2026 |
| Feb 27, 2026 | SOpen-market sale Common Stock10b5-1 | -120 | $481.50 | $58k | 137,758 | Mar 3, 2026 |
| Feb 27, 2026 | SOpen-market sale Common Stock10b5-1 | -240 | $482.84 | $116k | 137,518 | Mar 3, 2026 |
| Feb 27, 2026 | SOpen-market sale Common Stock10b5-1 | -2,510 | $487.13 | $1.2M | 135,008 | Mar 3, 2026 |
| Feb 27, 2026 | SOpen-market sale Common Stock10b5-1 | -3,278 | $488.27 | $1.6M | 131,730 | Mar 3, 2026 |
| Feb 27, 2026 | SOpen-market sale Common Stock10b5-1 | -460 | $489.32 | $225k | 131,270 | Mar 3, 2026 |
| Feb 27, 2026 | SOpen-market sale Common Stock10b5-1 | -2,725 | $490.54 | $1.3M | 128,545 | Mar 3, 2026 |
| Feb 27, 2026 | SOpen-market sale Common Stock10b5-1 | -949 | $491.30 | $466k | 127,596 | Mar 3, 2026 |
| Feb 27, 2026 | SOpen-market sale Common Stock10b5-1 | -2,520 | $493.29 | $1.2M | 125,076 | Mar 3, 2026 |
| Feb 27, 2026 | SOpen-market sale Common Stock10b5-1 | -3,498 | $494.33 | $1.7M | 121,578 | Mar 3, 2026 |
| Feb 27, 2026 | SOpen-market sale Common Stock10b5-1 | -15,580 | $495.38 | $7.7M | 105,998 | Mar 3, 2026 |
| Feb 27, 2026 | SOpen-market sale Common Stock10b5-1 | -5,995 | $496.16 | $3.0M | 100,003 | Mar 3, 2026 |
| Feb 27, 2026 | SOpen-market sale Common Stock10b5-1 | -1,725 | $496.95 | $857k | 98,278 | Mar 3, 2026 |
Related signals
Other insiders at VERTEX PHARMACEUTICALS INC / MA and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | VERTEX PHARMACEUTICALS INC / MA | Duncan McKechnie EVP, Chief Commercial Officer | $800k 1,541 shares | -12% | |
| 32Weak | VERTEX PHARMACEUTICALS INC / MA | Ourania Tatsis EVP, Chief Reg. & Quality Off. | $787k 1,500 shares | -3% | |
| 26Weak | VERTEX PHARMACEUTICALS INC / MA | Joy Liu EVP and Chief Legal Officer | $416k 828 shares | -4% | |
| 24Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $288k 596 shares | -4% | |
| 27Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $471k 1,020 shares | -6% | |
| 33Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $1.8M 4,062 shares | -19% | |
| 25Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $785k 1,745 shares | -8% | |
| 18Weak | VERTEX PHARMACEUTICALS INC / MA | Joy Liu EVP and Chief Legal Officer | $364k 828 shares | -4% | |
| 33Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $888k 1,974 shares | -8% | |
| 30Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $614k 1,354 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.